NewAmsterdam Pharma Stock (NASDAQ:NAMS)
Previous Close
$20.50
52W Range
$14.06 - $27.29
50D Avg
$18.16
200D Avg
$20.11
Market Cap
$2.36B
Avg Vol (3M)
$911.34K
Beta
-0.03
Div Yield
-
NAMS Company Profile
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NAMS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| MOLN | Molecular Partners AG |
| CMPX | Compass Therapeutics, Inc. |
| PRTC | PureTech Health plc |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| RZLT | Rezolute, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| IVA | Inventiva S.A. |
| REPL | Replimune Group, Inc. |
| MRUS | Merus N.V. |
| CGEM | Cullinan Oncology, Inc. |
| JANX | Janux Therapeutics, Inc. |
| PEPG | PepGen Inc. |